medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2023, Number 6

<< Back

Rev Mex Urol 2023; 83 (6)

Synchronous Primary Testicular Tumor: a case report of diffuse large B-cell lymphoma

Gilmar PS, Vitor PXG, Dantas OCF

Language: Spanish
References: 16
Page: 1-6
PDF size: 256.68 Kb.


ABSTRACT

Case description: 63-year-old man of with 7-month history of progressive and gradual increase in testicular size without pain, symptoms of local or systemic infection. Biomarkers for testicular neoplasia were within the reference range: LDH(167 U/L), AFP( 1.49 IU/mL), and HCG( 0.2 mUI/mL). MR): enlarged testicular dimensions showing nodular lesions of heterogeneous enhancement. The patient initially underwent a inguinal orchiectomy who revealed diffuse large B-cell lymphoma.
Relevance: primary testicular lymphoma (PTL) is a rare non-Hodgkin lymphoma (NHL) that occurs in 1–2% of all cases of NHL and commonly presents as diffuse large B-cell lymphoma in 80– 90% of cases. Bilateral and synchronous lesions are observed in 1–2% and 10% of cases, respectively. In this report, we describe our experience regarding this cancer.
Clinical implications: if not properly conducted, it can end in advanced disease with no prospect of cure, infertility, primary hypogonadism and psychological alterations due to the removal of the gonads.
Conclusions: PTL is a rare malignancy associated with high recurrence rates and poor prognosis, and multimodal therapy is warranted to achieve better long-term survival and cure rates.


REFERENCES

  1. Laguna MP, Albers P, Algabara F, BokemeyerC, Boormans J L, Fischer S, et al. EUA Guidelineson Testicular Cancer. 2020.

  2. Sia NPX, Chekrine T, Bourhafour M, Ouadii K,Bouchbika Z, Benchakroun N, et al. PrimaryTesticular Lymphoma: A Case Report andReview of the Literature. Journal of CancerTherapy. 2022;13(3): 145–154. https://doi.org/10.4236/jct.2022.133011.

  3. Campobasso D, Ferretti S, Frattini A.Synchronous bilateral testis cancer: clinicaland oncological management. ContemporaryOncology. 2017;21(1): 70–76. (8).

  4. Medina AA, Lorca Álvaro J, Carretero del BarrioI, Laso García I, García Cosío M, Mata AlcarazM, et al. Primary testicular lymphoma: Clinicalcharacteristics and oncological outcomes.Current Urology. 2023;17(2): 130–134. https://doi.org/10.1097/cu9.0000000000000137

  5. Rossi A, Orecchioni S, Falvo P, Tabanelli V,Baiardi E, Agostinelli C, et al. Dual targeting ofthe DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma. Leukemia.2022;36(1): 197–209. https://doi.org/10.1038/s41375-021-01347-6.

  6. Zhi Y, Bao S, Mao J, Chai G, Liu C, Zhu J.Development and validation of a survivalnomogram in patients with primarytesticular diffuse large B-cell lymphoma. TheJournal of International Medical Research.2023;51(9): 3000605231197052. https://doi.org/10.1177/030006052311970.

  7. Shing Oh K, Prajapati S, Mahalingam M. Diffuselarge B-cell lymphoma of the skin and testis: Adiagnostic and staging dilemma. Indian Journalof Dermatology, Venereology and Leprology.2023;89(1): 79–81. https://doi.org/10.25259/ijdvl_882_2021.

  8. Liu KT, Chang YC, Lin YC, Chang JL. Unusuallyaggressive primary testicular diffuse large B-celllymphoma initially presenting as systemicdisseminating metastases in older adult men:a case report. Annals of Medicine and Surgery(2012). 2023;85(8): 4106–4111. https://doi.org/10.1097/ms9.0000000000001018.

  9. Sehn LH, Salles G. Diffuse Large B-CellLymphoma. The New England Journal ofMedicine. 2021;384(9): 842–858. https://doi.org/10.1056/nejmra2027612.

  10. Trama F, Illiano E, Aveta A, Pandolfo SD,Bertuzzi G, Costantini E. Bilateral Primarytesticular diffuse large B-CELL lymphoma.Urology Case Reports. 2021;38: 101733. https://doi.org/10.1016/j.eucr.2021.101733.

  11. Singh R, Shaik S, Negi BS, Rajguru JP, Patil PB,Parihar AS, et al. Non-Hodgkin’s lymphoma: Areview. Journal of Family Medicine and PrimaryCare. 2020;9(4): 1834–1840. https://doi.org/10.4103/jfmpc.jfmpc_1037_19.

  12. Orellana-Noia V, Abousaud A. SecondaryCentral Nervous System Lymphoma: Updates inTreatment and Prophylaxis Strategies. CurrentTreatment Options in Oncology. 2022;23(10):1443–1456. https://doi.org/10.1007/s11864-022-01017-4.

  13. King RL, Goodlad JR, Calaminici M, Dotlic S,Montes-Moreno S, Oschlies I, et al. Lymphomasarising in immune-privileged sites: insightsinto biology, diagnosis, and pathogenesis.Virchows Archiv: An International Journal ofPathology. 2020;476(5): 647–665. https://doi.org/10.1007/s00428-019-02698-3.

  14. Spinner MA, Advani RH. Current FrontlineTreatment of Diffuse Large B-Cell Lymphoma.Oncology (Williston Park, N.Y.). 2022;36(1): 51–58. https://doi.org/10.46883/2022.25920940.

  15. Schepisi G, De Padova S, De Lisi D, Casadei C,Meggiolaro E, Ruffilli F, et al. Psychosocial Issuesin Long-Term Survivors of Testicular Cancer.Frontiers in Endocrinology. 2019;10: 113.https://doi.org/10.3389/fendo.2019.00113.

  16. Elenkov A, Giwercman A. Testicular DysfunctionAmong Cancer Survivors. Endocrinology andmetabolism clinics of North America. 2022;51(1).https://doi.org/10.1016/j.ecl.2021.11.014.




2020     |     www.medigraphic.com